RIGEL PHARMACEUTICALS, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
RIGEL PHARMACEUTICALS, INC. (RIGL) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $600.00 thousand as of 2022-12-31, per its 10-Q filed 2023-11-07.
Discontinued › Notes
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2023-11-07
- 2022-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $600.00K.
- 2021-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $100.00K.
- 2020-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $185.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2022-12-31 | $600.00K 10-Q · filed 2023-11-07 |
| 2021-12-31 | $100.00K 10-Q · filed 2022-11-03 |
| 2020-12-31 | $185.00K 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |